Literature DB >> 6600699

Emergency endoscopic sclerotherapy for bleeding esophageal varices: a prospective study in patients not responding to balloon tamponade.

W E Fleig, E F Stange, K Ruettenauer, H Ditschuneit.   

Abstract

To assess the efficacy of endoscopic paravariceal sclerotherapy (EPS) compared to balloon tamponade, 25 patients with massive hemorrhage from esophageal varices not responding to Sengstaken or Linton tube tamponade were treated by emergency EPS. None of the patients had received vasopressin. Immediate control of hemorrhage was achieved in 92%. Recurrent bleeding occurred in 17.4% of patients during their primary admission. Minor complications resulting from EPS were observed in three patients (12%): esophageal ulcer, esophageal stenosis, and pleural effusion. Ten patients (40%) died in the hospital, seven of them despite arrested hemorrhage. Fifteen patients were discharged and followed at 3-month intervals for a mean of 21.3 months (range, 8.8 to 29.7). During this period one death due to liver failure without recurrent hemorrhage and three rebleeding events in two patients were observed (rebleeding risk per patient month, 9.4 x 10(-3). We conclude that EPS is very effective in controlling acute bleeding from esophageal varices, even in poor risk patients with ineffective balloon tamponade.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6600699     DOI: 10.1016/s0016-5107(83)72489-2

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  10 in total

1.  Technique and early clinical results of endoscopic variceal ligation (EVL).

Authors:  G V Stiegmann; J S Goff; J H Sun; D Davis; D Silas
Journal:  Surg Endosc       Date:  1989       Impact factor: 4.584

2.  Intramural hematoma of the esophagus: unusual complication of variceal sclerotherapy.

Authors:  W Van Steenbergen; J Fevery; L Broeckaert; E Ponette; A Baert; J De Groote
Journal:  Gastrointest Radiol       Date:  1984

3.  Gastric ulcer after prophylactic balloon-occluded retrograde transvenous obliteration.

Authors:  Yoshitaka Takuma; Kazuhiro Nouso; Hiroki Takayama; Yasuhiro Makino; Shunsuke Saito; Shouichi Tanaka; Masatoshi Ogata; Takeyuki Ohta; Junichi Kubota; Masaya Iwamuro
Journal:  J Gastroenterol       Date:  2007-03-30       Impact factor: 7.527

Review 4.  The evolving role of endoscopic treatment for bleeding esophageal varices.

Authors:  J E J Krige; J M Shaw; P C Bornman
Journal:  World J Surg       Date:  2005-08       Impact factor: 3.352

5.  Immediate endoscopic sclerosis of bleeding esophageal varices. A prospective evaluation over five years.

Authors:  K J Paquet; J F Kalk; P Koussouris
Journal:  Surg Endosc       Date:  1988       Impact factor: 4.584

6.  Balloon-occluded retrograde transvenous obliteration for gastric variceal bleeding: its feasibility compared with transjugular intrahepatic portosystemic shunt.

Authors:  Young Ho Choi; Chang Jin Yoon; Jae Hyung Park; Jin Wook Chung; Jong Won Kwon; Guk Myung Choi
Journal:  Korean J Radiol       Date:  2003 Apr-Jun       Impact factor: 3.500

Review 7.  Sclerotherapy for bleeding esophageal varices after randomized trials.

Authors:  D A Lieberman
Journal:  West J Med       Date:  1986-10

8.  Comparison of the two time schedules for endoscopic sclerotherapy: a prospective randomised controlled study.

Authors:  S K Sarin; G Sachdev; R Nanda; S K Batra; B S Anand
Journal:  Gut       Date:  1986-06       Impact factor: 23.059

9.  Comparison of postoperative results following terminal esophagoproximal gastrectomy and esophageal transection for esophageal varices.

Authors:  H Shiozaki; S Tamura; K Kobayashi; H Yano; H Tahara; Y Kido; S Mizunoya; K Okagawa; Y Ogawa; T Mori
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

10.  Esophageal motility and symptoms after endoscopic injection sclerotherapy.

Authors:  L B Cohen; C Simon; M A Korsten; E J Scherl; J Skorniky; M B Guelrud; J D Waye
Journal:  Dig Dis Sci       Date:  1985-01       Impact factor: 3.199

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.